AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00750113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifidipine
Description: Tablets 20 Mg daily for 4 weeks then combination therapy
Study NCT00750113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Description: Tablets 80 Mg daily for 4 weeks then combination therapy
Study NCT00750113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine/Telmisartan
Description: 2 drugs (20 Mg Nifedipine/80 Mg Telmisartan) Combination therapy since the beginning
Study NCT03805737 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amulez and sunlight
Description: Amulez and sun exposure for 2 hours
Study NCT03805737 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Amulez and red light treatment
Description: Amulez and red light treatment for 10 minutes
Study NCT04583605 — intervention group
Intervention type: DEVICE
Intervention: PREVENA
Description: A negative pressure wound closure therapy is used after lymph node dissection
Study NCT04263753 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bladder conservative surgery in placenta accretta
Description: After control of both superior vesical vessels Finding a fresh noninvaded plan between isthmocervical junction and posterior bladder wall aided by filling the bladder 150 cc saline Then cervical stump control sutures and severing the specimen above the clamps~\* Now the placenta is only attached to the bladder , apply intestinal clamp or foley cath on the bladder below the level of invasion if feasible to reduce bleeding~\* cut through the placenta, heavy back flow bleeding of old blood stored in the placenta will be noticed , but there is no hemodynamic change since the cervical stump is already severed~, dissect the bladder with a large safety margin cutting through the placenta.. Then in cases with hematuria saline irrigation of the bladder is usually enough to clear the hematuria 15 out of 20
Study NCT05956275 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Tramadol
Description: ACB and IPACK were performed in USG-guided adductor canal block and infiltration popliteal artery capsule knee block accompanied by USG, Bupivacaine and 10 mL of 0.9% NaCl were applied in each block application.
Study NCT05956275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: ACB and IPACK were performed in USG-guided adductor canal block and infiltration popliteal artery capsule knee block accompanied by USG, Bupivacaine and 10 mL of 0.9% NaCl were applied in each block application.
Study NCT05956275 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Morfin
Description: No block was applied to the patients in control
Study NCT05956275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morfin
Description: No block was applied to the patients in control
Study NCT03581903 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H7N3 pLAIV
Description: Approximately 10\^7.0 fluorescent focus units (FFUs) administered intranasally by an Accuspray device
Study NCT03581903 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H7N9 pIIV
Description: 30 micrograms administered by intramuscular (IM) injection
Study NCT01486290 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral
Description: the intervention included developing strategies to help patients cope with their barriers to self care. The intervention were implemented by an office based educator over a six month by phone calls. From six months to twelve months subjects did not have any contact with study staff.
Study NCT00886795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abatacept (Orencia ®)
Description: 4 doses of abatacept administered intravenously at baseline, 2 weeks, 4 week, and 8 weeks.
Study NCT02060370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Starting dose: 50 mg by mouth daily given for 2 weeks on followed by 1 week off. 1 cycle is 6 weeks.
Study NCT02060370 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaire completion on Day 1 of Cycle 1, and on Day 35 of Cycles 2, 4, and 6.
Study NCT00261755 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Based on international experiences and experiences from the pilot project 34 specified acupuncture points could be used.Treatment was individualised according to the woman's mobility and localization of pain. Needles were sterile stainless steel acupuncture needles in three lengths: 0.20 x 15 mm, 0.30 x 30 mm and 0.35 x 50 mm. No electric stimulation was used. The duration of needling could vary from 30 minutes to two hours and could be repeated. The needles were removed if the patient felt uncomfortable or in cases with obstetric pathology.
Study NCT00261755 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TENS
Description: The Transcutaneous Electric Nerve Stimulation (TENS treatment) was carried out using a B.C - TENS 120Z unit. Two to four electrodes were placed on the skin of the lower back. The units were set in constant mode, initially with a pulse width of 60 micro-seconds and a pulse rate of 100 pulses per second. The treatment lasted from 20 to 45 minutes and could be repeated. The intensity of stimulation could be adjusted by the woman or the midwife.
Study NCT00261755 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Group
Description: All analgesic methods available (Sterile water papules, nitro oxygen, bath tub, pethidine and epidural analgesics (EDA)). A specific analgesic was chosen by the woman and the midwife after informed choice.
Study NCT04604834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PFAT first
Description: Week 1 to week 4: one eyedrop of PFAT (preservative-free artificial tears) every 2 hours. Week 5 to week 8: one eyedrop of APRP (autologous plasma rich platelet) every 2 hours. Week 9 to week 12: one eyedrop of PFAT and APRP every 2 hours.
Study NCT04604834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APRP first
Description: Week 1 to week 4: one eyedrop of APRP every 2 hours. Week 5 to week 8: one eyedrop of PFAT every 2 hours. Week 9 to week 12: one eyedrop of PFAT and APRP every 2 hours.
Study NCT03869372 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: In subsequent sessions, the same measures of autonomic activity and MEPs will be monitored but different patterns of repetitive TMS (rTMS) will be applied to motor cortex or other areas before the test meal, water or nutrient drink is consumed.
Study NCT04541563 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Fisher Wallace Cranial Electrotherapy Stimulator Device
Description: Fisher Wallace Stimulator®, a patented cranial electrotherapy stimulation device that was cleared by the FDA in 1991 for the treatment of depression, anxiety and insomnia.
Study NCT02703259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Study NCT02703259 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Study NCT04541563 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fisher Wallace Cranial Electrotherapy Stimulator Device
Description: Fisher Wallace Stimulator®, a patented cranial electrotherapy stimulation device that was cleared by the FDA in 1991 for the treatment of depression, anxiety and insomnia.
Study NCT02703259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Study NCT02703259 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Celecoxib
Study NCT02703259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Study NCT02837003 — intervention group
Intervention type: DRUG
Intervention: Aspirin
Description: Discontinuation of aspirin at 3 months after the Ultimaster sirolimus-eluting stent implantation by the physician's discretion.
Study NCT04564001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Patients will receive infliximab 5mg/kg intravenously at week 0; 2; 6; 14; 22 in arm A
Study NCT04564001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Patients will receive tocilizumab 8mg/kg intravenously at week 0; 4; 8; 12; 16; 20; 24 in arm B
Study NCT01200706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: amoxicillin 50mg/kg/day given in two different administration schemes
Study NCT02837003 — intervention group
Intervention type: DRUG
Intervention: Thienopyridine
Description: Discontinuation of thienopyridine at 3 months after the Ultimaster sirolimus-eluting stent implantation by the physician's discretion.
Study NCT01565278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Soybean oil (Standard treatment)
Description: 1. Standard treatment: Soybean oil based emulsion: 0.25 g/kg/TPN day
Study NCT01565278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soybean oil + Fish oil
Description: Intralipid+Omegaven: 0.25 g/kg/TPN Intralipid day+0.4 g/kg/TPN Omegaven day for 6 months
Study NCT03198468 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bronchoscopic Thermal Vapor Ablation
Description: Vapor (steam) is infused into the targeted region for 8 seconds at a precisely controlled flow rate and power (an energy level of 330 calories).
Study NCT03847740 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Isometric Trumb Force handle
Description: Compare the pattern of neuromuscular blocking drug between two devices applied on the same patient during general anesthesia.
Study NCT04166604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/Tipiracil
Description: After morning and evening meal~Days 1 through 5: 35mg/m2 (twice daily)~Days 6 through 7: recovery~Days 8 through 12: 35mg/m2 (twice daily)~Day 13 through 28: recovery
Study NCT01622933 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC Vaccine + IFN
Description: Vaccine: The dose target is 1x10e7 AdVTMM2/DC per intradermal injection, or lower dose per sponsor's discretion.~IFN: 20 MU/m²/d (rounded to the nearest 1.0 million unit) administered IV x 5 consecutive days out of 7 (M-F) every week x 4 weeks.
Study NCT01622933 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdVTMM2/DC Vaccination
Description: Vaccine: The dose target is 1x10e7 AdVTMM2/DC per intradermal injection.If cell counts are below the target, as few as 5x10e6 AdVTMM2/DC may be administered. However, at the discretion of the sponsor and/or the treating physician, a lower dose of DC that fulfills all of the other criteria for release may be administered on a case by case basis. If this occurs a dose exception form will be completed by the IMCPL, signed by the treating physician and filed in the subjects research records.
Study NCT02021292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Macitentan 10 mg, oral tablet, to be taken once daily.
Study NCT02021292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo oral tablet, to be taken once daily.
Study NCT04331691 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: After randomization, this group will receive 12.5 mg of spironolactone daily. Subjects who did not reach the target blood pressure after 4 weeks of treatment should be increased to 25 mg of spironolactone. After 12 weeks of treatment, study will be end.
Study NCT04331691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiloride
Description: After randomization, this group will receive 5 mg of amiloride daily. Subjects who did not reach the target blood pressure after 4 weeks of treatment should be increased to 10 mg of amiloride. After 12 weeks of treatment, study will be end.
Study NCT00370500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine fumarate
Description: Dosage and frequency are judged by the study physician. The dosage must not excess 800mg/d.
Study NCT05504317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK111
Description: Subjects will receive one of four escalated doses of AK111 (75mg/150mg/300mg/450mg) injection subcutaneously.
Study NCT02353026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Artesunate
Description: Intravenous Artesunate in escalating doses: 8, 12, 18, 25, 34, 45 mg/kg on days 1 and 8 of every 3 week cycles
Study NCT01885013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin + Myocet + Cyclophosphamide
Description: Metformin + Myocet + Cyclophosphamide:~Metformin 1000 mg, 2 times daily per os\*. Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Chemotherapy will be performed for 8 cycles Cyclophosphamide 600 mg/m2, intravenous infusion, at day 1 every 21 days.~\* During cycle 1, patients will assume only metformin from day 1 to day 13 and will begin chemotherapy from day 14. From day 1 to day 3, patients will assume Metformin 1000 mg once a day. Starting from day 4 patients will assume Metformin 1000 mg 2 times a day.
Study NCT01885013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myocet + Cyclophosphamide
Description: Myocet + Cyclophosphamide:~Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Cyclophosphamide 600 mg/m2, intravenous infusion, on day 1, every 21 days Chemotherapy will be performed for 8 cycles
Study NCT04479839 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound of the airway
Description: Placing ultrasound on the neck after intubation
Study NCT00676403 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo control (capsule), once a day, 1- 3 hours before bedtime for 6 weeks
Study NCT00676403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: 50 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
Study NCT00676403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: 100 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
Study NCT00676403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: 150 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
Study NCT00676403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: 300 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
Study NCT00676403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: 450 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
Study NCT05259488 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: immunonutrition
Description: nutridrinks 3 times a day 5 days prior surgery plus maltodextrins the day of surgery
Study NCT01162616 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: labeled iron solutions
Description: labeled iron as 2 mg 58FeSO4, 57FeSO4 or 54FeSO4 per test portion (50g sorghum) 2 mg labeled iron as NaFeEDTA per test portion (50g sorghum)
Study NCT03999502 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endomina
Description: The procedure will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over a guidewire and then fixed to the endoscope. The procedure will include at least one suture of the gastric cardia to tighten it. Patients will be kept overnight after the procedure.
Study NCT02150928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)
Description: * Enrolled patients will receive asparaginase Erwinia chrysanthemi 25,000 IU/m2 administered intramuscularly (IM) on a Monday/Wednesday/Friday schedule (all dosing regimens will start on a Monday)~* All patients will receive at least 1 course (2 weeks) of treatment with asparaginase Erwinia chrysanthemi (1 course=6 doses), and a maximum number of courses needed to complete their remaining asparaginase therapy (up to 15 courses)~* Eligible patients may not begin treatment with asparaginase Erwinia chrysanthemi until their serum asparaginase activity level is below the assay detectable limit
Study NCT00924924 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Act Healthy!
Description: Six-week class of 50 minute sessions of self-management training for health behaviors
Study NCT00924924 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Act Healthy!
Description: Six-week class of 50 minute sessions of self-management training for health behaviors
Study NCT00924924 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed treatment control
Description: Delayed self-management training group - begins following completion of the experimental group training
Study NCT01372046 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Booster Sessions
Description: Provides onsite booster sessions for one year to the group after participating in standard care
Study NCT01372046 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: memorandums, staff meetings
Study NCT03918057 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy for Insomnia
Description: Cognitive behavioural therapy for insomnia (CBT-I) is an evidence-based psychotherapeutic intervention that combines cognitive and behavioural principles. Specifically, this therapy provides psychoeducation about thoughts contributing to the maintenance of sleep problems, and instruction in behavioural techniques to help decrease sleep onset latency and promote effective sleep maintenance.
Study NCT03918057 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Participants will receive regular obstetric care and will be placed on a wait-list for CBT-I treatment after their final assessment. All activities women try for improving their own sleep problems between assessments will be recorded and coded for.
Study NCT00678418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIVITROL® 380 mg
Description: Administered via intramuscular (IM) injection once every 4 weeks for 24 weeks during Part A, followed by once every 4 weeks for 52 weeks in Part B.
Study NCT00678418 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered via IM injection once every 4 weeks for 24 weeks during Part A, followed by VIVITROL® 380 mg via IM injection once every 4 weeks for 52 weeks in Part B.
Study NCT02936375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iguratimod
Description: 25mg twice a day, orally administrated
Study NCT02936375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 1g/m², every 4 weeks, intravenous
Study NCT02936375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: 2mg/kg·d, once a day, orally administrated
Study NCT02936375 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroids
Description: Prednisone, methylprednisolone or prednisonlone, once a day, orally administrated. Steroids should be 1mg/kg·d in the beginning four weeks, then tapered 5-10mg/d every two weeks till 30mg/d, then tapered 2.5-5mg/d every two weeks. After 24 weeks of follow-up, a patient should receive steroids no more than 10mg/d. Patients may receive temporal high dose of steroids (1mg/kg·d) because of symptoms outside of kidney, for no more than two weeks. All the dosage of steroids above is calculated by prednisone.
Study NCT05504317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive corresponding dose of placebo injection subcutaneously.
Study NCT02427945 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provision of information on safe water
Description: A promoter from Evidence Action will visit the household and provide information on safe water.
Study NCT02427945 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provision of information on safe water and child nutrition
Description: A promoter from Evidence Action will visit the household and provide information on safe water, as well as child nutrition (including hygiene on food preparation and storage). Households will be given a poster to hang in their dwellings with basic nutrition information. The poster might be smaller and in black and white, or larger and in color.
Study NCT02006524 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 'MyDiagnostick
Study NCT01223352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosentan
Description: 32 mg quadrisected dispersible tablet. The dosage of bosentan (2 mg/Kg) was adjusted according to the patient's body weight at initiation of the study treatment. Dosage readjustment was permitted after 12 weeks of treatment.
Study NCT03162198 — intervention group
Intervention type: OTHER
Intervention: Cirrhosis with HCC
Description: Cirrhosis with Hepatocellular Carcinoma
Study NCT03162198 — intervention group
Intervention type: OTHER
Intervention: Cirrhosis without HCC
Description: Cirrhosis without Hepatocellular Carcinoma
Study NCT05595252 — intervention group
Intervention type: BIOLOGICAL
Intervention: cervical biopsy
Description: cervical biopsy made during and after pregancy
Study NCT02881346 — intervention group
Intervention type: DRUG
Intervention: Enstilar®
Description: Once daily application of cutaneous foam to plaques on body and/or extremities
Study NCT04094441 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chest physiotherapy
Description: chest physiotherapy
Study NCT03083418 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: control group
Description: No EDP treatment